SUMMARY Portal fibrosis is considered to be pivotal in the pathogenesis of portal hypertension associated with extrahepatic biliary obstruction. The histological features, however, include diffuse hepatocyte hyperplasia as well as portal fibrosis, but not cirrhosis, and it is possible that the contribution of hepatocyte hyperplasia in the initiation of portal hypertension is equally important. If so, we hypothesised that patients with biliary obstruction and a coincident condition such as liver atrophy, or hepatic resection, with the potential of accelerating the hepatocyte proliferation caused by biliary obstruction itself, might be expected to develop portal hypertension earlier than patients with biliary obstruction alone. To examine this concept we studied 10 patients with postcholecystectomy bile duct stricture, portal hypertension and liver atrophy, or hepatic resection (group I) and compared them with nine patients with postcholecystectomy stricture and portal hypertension, but no atrophy or resection (group II). Portal hypertension was diagnosed a mean 28 months (range 18-48 months) after cholecystectomy in group I compared with 62 months (range 36-100 months) for patients in group II (p<O0OO5 Mann-Whitney test). Thus hepatocyte hyperplasia may be an important part of the mechanism underlying the development of portal hypertension in chronic biliary disease.
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Diffuse hepatocyte hyperplasia and extensive portal fibrosis, but not cirrhosis, are the histological changes observed in most cases of portal hypertension associated with chronic bile duct obstruction.' Many reports have emphasised that the onset of portal hypertension is primarily the result of the early development of fibrosis.' The contribution of hepatocyte hyperplasia, however, may also be important and it is possible that in some cases portal hypertension is initiated by bile duct obstruction and a concomitant condition that has accelerated the hepatocyte hyperplasia induced by biliary obstruction itself. Patients with such disease might be at risk of developing portal hypertension at an earlier stage than patients with biliary obstruction alone. A significant number of patients with benign high biliary obstruction have liver atrophy,5 which has been shown experimentally to be a potent stimulus of hepatocyte hyperplasia. (Figure) . Liver biopsy specimens were obtained in 22 patients at the end of a surgical procedure. Depending on the presence of portal hypertension or atrophy, or both, three groups were studied: Group I comprised 10 patients (seven men and three women, mean age 45 years) with bile duct obstruction, portal hypertension, and lobar liver atrophy (nine cases) or bile duct obstruction, portal hypertension and previous partial hepatectomy (one case). This patient had undergone right lobectomy in a previous attempt to repair a high bile duct stricture which subsequently recurred.
Group II consisted of nine patients (four men and five women, mean age 52 years) with bile duct obstruction and portal hypertension but without obvious atrophy.
Group III contained five patients (two men and three women, mean age 55 years) with bile duct obstruction and lobar atrophy (four cases) or segmental atrophy (one case) but no portal hypertension. These patients had been investigated in a manner comparable with those in groups I and II but only three underwent repair of bile duct stricture; the other two had only unilateral hepatic duct obstruction and were treated conservatively.
The criteria on which portal hypertension was diagnosed were as follows: group I: raised portal pressure (measured at surgery by cannulation of a The mean number of surgical procedures done before the diagnosis of portal hypertension was reached was 2 3 in group I and 2 8 in group II. The corresponding figure for group III is two. The frequency of cholangitic episodes and the treatment instituted were similar.
The duration of disease was considered to be the time since an operative ductal injury had been recorded during cholecystectomy up to the time portal hypertension was firstly diagnosed. Because the ductal injury that eventually caused atrophy may not have always been inflicted during the operation of cholecystectomy but at a later procedure undertaken to correct a formed stricture, it is likely that the interval between the development of atrophy and the The mean duration and range of disease was 28 months (range 18-48 months) in group I, 62 months (range 36-100 months) in group II and 42 months (range 28-72 months) in group III. The difference between the two groups with portal hypertension (group I and group II) is statistically significant (p<0O005). In group I, the mean duration of disease was 28 months in the nine patients with atrophy and 24 months in the patient with previous hepatic resection. In group III, the duration of disease in the two patients with diffuse hyperplasia and limited fibrosis was 28 and 32 months, 30 months in the patient with extensive fibrosis and 48 and 72 months in the other two patients with unilobar obstruction.
FOLLOW UP
None of the five patients in group III, and in particular the patient with diffuse hyperplasia and extensive fibrosis, has shown any signs of developing portal hypertension in a mean follow up period of 48 months. The effect of successful reconstructive biliary surgery on the progress of portal hypertension in group I and II patients is currently being studied.
Discussion
Portal hypertension develops in about 20% of patients with chronic bile duct obstruction and has been associated with a bad prognosis. I(J12 The 30 day hospital mortality in 11 such patients reported recently was 36% compared with 3-2% for patients with comparable bile duct obstruction but without portal hypertension."' Although many risk factors have been identified for the development of portal hypertension, including a protracted course of obstruction and frequent episodes of cholangitis,"' 12 their contribution to the structural changes occurring in the liver has not been analysed. This may reflect the prevailing notion that the mechanism of obstruction to the portal flow is the same as that which has been postulated for the more common forms of hepatic cirrhosis -that is, the existence of hyperplastic nodules.2 It is worth noting, however, that hepatocyte hyperplasia in portal hypertension consequent on large duct obstruction is distinctly lobular rather than nodular in pattern. ' Lobar atrophy of the liver usually signifies hepatic duct obstruction, or portal venous occlusion, to the site of atrophy.' 617 The contralateral lobe undergoes striking compensatory hypertrophy and hyperplasia. 6 Experimental studies indicate that hepatocyte proliferation initiated by liver atrophy is comparable in time and intensity with the adaptive hyperplastic response observed after liver resection.6' 1 Although other factors may have contributed, it is interesting that the single patient with previous hepatic lobectomy in group I developed portal hypertension close to the mean time of the other nine patients with atrophy in the same group. It is perhaps worth noting, however, that lobar atrophy consequent on unilateral hepatic duct obstruction or portal venous occlusion does not lead to portal hypertension and can be asymptomatic provided the contralateral lobe enjoys normal portal flow and normal biliary drainage'9 as shown by the two patients with unilobar obstruction in group III. If, after the development of liver atrophy, the hepatic duct draining the contralateral hypertrophied lobe becomes obstructed also,'7 the relevant liver tissue is subjected to the development of periportal fibrosis and destruction of hepatocytes adjacent to the expanding portal tracts,'2 thus providing a powerful stimulus for further proliferation within the remaining hepatocyte population.' Even though a sequence of fibrosis leading to loss of hepatocytes and the initiation of hepatocytic hyperplasia is conceptually plausible, the temporal relation of the phenomena involved and the effect that other factors such as infection might have on that sequence are not known. Suffice to say that extensive fibrosis and progression to biliary cirrhosis occurs regularly in experimental bile duct obstruction in the absence of infection.2" Many clinical studies have shown a correlation between the frequency of cholangitic episodes and the subsequent development of portal hypertension'2"2 but in one study the inverse correlation was observed between cholangitis and biliary cirrhosis.' Moreover, the fibrosis of uncomplicated ductal obstruction cannot be discriminated from the fibrosis of 'infected biliary cirrhosis'. 22 The average time of five years taken for portal hypertension to develop in patients without atrophy (group II) is in accord with reported figures." 12 Although the onset of portal hypertension under two years in some cases of bile duct obstruction has been noted by others, no causative factors were identified and no conclusions were drawn as to the operative mechanisms.'2 The results of this study suggest that the contribution of hepatocyte hyperplasia to the development of portal hypertension in chronic biliary obstruction is substantial and important. While bile duct obstruction effects a degree of periportal hepatocyte hyperplasia which may become diffuse if the obstruction is unrelieved,' an early generation of hepatocyte hyperplasia by an appropriate stimulus may considerably shorten the time required for hypertension to develop.
It is of interest that one patient in group I had portal hypertension in the presence of limited periportal fibrosis as assessed in sections from a sizeable piece of liver removed to facilitate surgical access. Although we have not encountered a case of extrahepatic duct obstruction and portal hypertension not associated with diffuse hepatocyte hyperplasia, it may be that extensive periportal fibrosis is not essential for hypertension to develop. On the other hand, an explanation for the absence of demonstrable portal hypertension in three patients with diffuse hyperplasia in group III is not obvious although it is noted that two of them had only limited fibrosis. Portal hypertension was diagnosed on clinical and imaging signs generally regarded as indicating a raised portal pressure but it has been remarked that their absence does not exclude a high portal pressure in extrahepatic biliary disease." 2 Furthermore, our hypothesis predicts an increased risk rather than a certainty of early portal hypertension and it may be pertinent to speculate that had these three patients not been submitted to successful biliary drainage at around 30 months after cholecystectomy, with the expected resolution of fibrosis and the arrest of further hepatocyte proliferation, they might still have developed portal hypertension within the time range of patients with atrophy in group I, or, at any rate, earlier than patients without atrophy in group II. Thus in the light of this and other recent work' it seems that both component processes are important and it may be untenable to view portal fibrosis as the critical factor in the pathogenesis of portal hypertension in chronic bile duct disease without reference to hepatocyte hyperplasia. 4 Progression of the hepatic disease and the development of oesophageal varices which have been noted in some patients with biliary obstruction after restoration of bile flow4"'" is disturbing and not readily understood, although such deterioration may not be unexpected with established true cirrhosis, incomplete biliary decompression,4"' or extrahepatic portal venous occlusion." Indeed, the significance of the observation that most patients with obstructive biliary disease and portal hypertension have no cirrhosis' rests with the distinct possibility of regression of structural changes in the liver including fibrosis consequent upon successful biliary drainage. 24 The recommended practice of early and efficient relief of bile duct obstruction4 cannot be overemphasised in cases where a coincident disease causing hepatocyte proliferation is in operation.
Finally, our hypothesis may also explain the pathogenesis of portal hypertension that occasionally develops after relief of biliary obstruction that has necessitated liver resection, a sequence that we observed in one of 16 patients with hilar cholangiocarcinoma undergoing hepatic resection. Investigations revealed patency of the ductal anastomosis and vascular channels, and it is possible that a slower than normal resolution of extensive portal fibrosis secondary to obstruction in association with the development of diffuse hepatocyte hyperplasia consequent on resection account for the outcome in this patient. Experimental data show early return of portal pressure and liver perfusion to normal after hepatic resection25 and although acute portal hypertension has been reported to occur after hepatic resection in patients without bile duct disease,26 this has not been confirmed in other series2' and we have not encountered it in 68 major resections with the exception of one case complicated by portal venous occlusion. 
